No Data
No Data
Tiankang Biology (002100): Rapid cost improvement, steady financial strength
The 2023 and 1Q24 results are in line with our expectations Tiankang Biotech announced 2023 and 1Q24 results: the company achieved revenue of 190.26/3.777 billion yuan in 2023/1Q24, +12 compared to the previous year
Tiankang Biotech (002100) 2023 Annual Report and 2024 Quarterly Report Review: Multiple businesses continued their growth trend and turned losses into profits in the first quarter
Incident: The company released its 2023 annual report and 2024 quarterly report on April 29. The full year of 2023 achieved revenue of 19.03 billion yuan, +12.0% year-on-year; realized net profit of 1.36 billion yuan to mother.
The fluctuation in pork stocks boosted Tiankang Biotech by more than 7%
Pork stocks fluctuated and rallied. Tiankang Biotech rose more than 7%, while Dongrui shares, Tang Renshen, Zhenghong Technology, Huatong shares, and Xinwufeng followed suit.
Tiankang Biotech (002100.SZ): Net profit of 54.638 million yuan for the first quarter reversed the year-on-year loss
Gelonghui, April 29丨Tiankang Biotech (002100.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 3.777 billion yuan, down 2.93% year on year; net profit attributable to shareholders of listed companies was 54.638 million yuan, which turned a year-on-year loss into a profit; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 56.773 million yuan; basic earnings per share were 0.04 yuan.
Tiankang Biology (002100): Pig prices are dragging down breeding losses and feed movements are growing steadily
Farming dragged down huge losses. Maintaining the “buy” rating, Tiankang Biotech released an annual report. In 2023, it achieved revenue of 19.026 billion yuan (yoy +11.99%), and net profit of 1,363 billion yuan (yoy-585).
China Galaxy Securities: 24Q2 pig prices or trends are improving, focus on breeding industry chain opportunities
Taking into account the length of losses in the industry, the extent of elimination of breeding sows, and the current situation of the spread of the winter epidemic, the historical low valuation of the industry is taken into account, and the focus is on high-quality pig companies with leading cost control and good financial resources.
No Data